NCT05393492 Regulating Emotions and Behaviors After Brain Injury
| NCT ID | NCT05393492 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Acquired Brain Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 77 participants |
| Start Date | 2022-05-19 |
| Primary Completion | 2022-05-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 77 participants in total. It began in 2022-05-19 with a primary completion date of 2022-05-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
After acquired brain injury (ABI), persons can experience emotional and behavioral difficulties, that can be painful both for the person and his/her family. This clinical study aims at measuring the effectiveness of a third wave cognitive behavioral therapy called "dialectical behavior therapy" (DBT). DBT aims at teaching persons emotion regulation skills, interpersonal effectiveness skills, mindfulness and distress tolerance skills through group and individual sessions. The study's hypothesis is that DBT, in an adapted format for persons with ABI can lead to * a better quality of life, emotional and behavioral regulation, and self-esteem * decrease in problematic behaviors * progress in life goals * increase post traumatic growth and spirituality * better family functioning and lesser burden for care givers * experiencing more emotions and more free will 45 persons with an ABI sustained more than 18 month back, will follow a 3 phases, follow-up with care as usual for 5 months, followed by 5 months of DBT, followed by 5 months of care as usual + DBT monthly sessions. Self- and family-questionnaire will explore quality of life, emotional regulation, self-esteem, stress, anxiety, cognitive difficulties, family functioning and coping, post traumatic growth and spirituality and will be compared across the 3 phases. Results will be analyzed at a group level but also at an individual level (each patient separately) to test for decrease in unwanted behaviors and at a dyadic level (the person and his/her spouse) to test for the mutual effect of regulating emotions. Persons' memories will by analyzed at 3 time points by a linguistic analysis, and experience of free will after ABI will be analyzed by transcribed narratives of participants.
Eligibility Criteria
Eligibility Criteria: \* (Limit: 15,000 characters) Summary criteria for participant selection. Main eligibility criteria GREMO patients : * Inclusion criteria: * Persons with acquired brain injury regardless of the type or location of the injury * Age between 18 and 68 * Over 18 months since the acquired brain injury (or 6 month if mild traumatic brain injury) * Challenging behaviors or emotional dysregulation or high level of anxiety / depression or family's complaints about emotional dysregulation * Secondary or exacerbated by an acquired brain injury * Causing important suffering for themselves or their families * Being affiliated to a social security * Fluent in French * Being able to understand goals and risks and to give a dated and signed consent * Exclusion criteria: * Clinically evident severe lack of insight, lack of abstract reasoning, or severe anosognosia * Patients without any complaints * Severe cognitive impairments, aphasia or intellectual impairments that doesn't allow to understand DBT skills, questionnaires or group intreactions * Non fluent in French * Associated brain degenerative disease * Cancerous brain injury with uncertain progression * Non-stabilized psychotic disorder * Following a third wave cognitive behavioral therapy during the research study (for example : acceptance and commitment therapy) Controls without brain injury * Inclusion criteria : * Being 18 years old or more * Without brain injury * Exclusion criteria : * Non fluent in French * History of brain injury or brain disease * History of psychiatric disorder * Personality disorder * GREMO patient's family member living together * Psychologist, neuropsychologist or people with an emotional regulation knowledge linked to their profession * Being under guardianship or curatorship * Being pregnant or breastfeeding GREMO patients' family members * Inclusion criteria : * Being 18 years old or more * GREMO patient's family member * Living with a GREMO patient * Agreeing to rate an emotion-behavior-skills diary cards * Exclusion criteria : * GREMO patient's refusal for their family member to participate * Non fluent in French * Brain injury or brain disease * Major lack of insight * Being under trusteeship or curatorship Qualitative research ABI patients and families * Inclusion criteria : * Person with ABI attending the same medico-social service as GREMO patients * Ineligible for GREMO patients group (participation refusal, major insight difficulty…) * Agreeing to talk about their free will or spirituality * Exclusion criteria : * Aphasia or dysarthria not allowing understandable recording * Impossibility to understand oral questions * Non fluent in French
Frequently Asked Questions
Who can join the NCT05393492 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acquired Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05393492 currently recruiting?
Yes, NCT05393492 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Strasbourg, France to inquire about joining.
Where is the NCT05393492 trial being conducted?
This trial is being conducted at Illkirch-Graffenstaden, France.
Who is sponsoring the NCT05393492 clinical trial?
NCT05393492 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 77 participants.